Seeking Alpha

instudy

instudy
Send Message
View as an RSS Feed
View instudy's Comments BY TICKER:
Latest  |  Highest rated
  • Gilead Could Be A Smart Play On Hepatitis C Market Growth [View article]
    I was cured in the phase ll Pharmassett (Gilead) / BMS all oral Hep C trial and it greatly saddens me that over 1000 people a month die from Hep C in this country and that a cure exists.
    Jan 28, 2013. 01:59 PM | Likes Like |Link to Comment
  • Gilead Could Be A Smart Play On Hepatitis C Market Growth [View article]
    180,000 people have died of Hep C since Gilead stopped their study with BMS.... they boasted a 100% cure rate for the combination cure. This company needs to get some compassion and wake up to the fact we are judged, not by financial gain alone. We are here on this earth to help one another. They certainly would not go broke entering a phase lll trial with BMS. Vaccines are right around the corner and baby boomers with Hep C are passing away, if they wait much longer they will post a loss, even with a miracle drug.
    Jan 28, 2013. 01:57 PM | Likes Like |Link to Comment
  • Medgenics' Bulging Pipeline Of Blockbuster Indications Takes On Big Pharma's Harmful Drugs [View article]
    Every body is unique and has a special set of circumstances associated with it, life style, heredity and so forth. Creating a drug to eliminate diseases is very difficult and often the process appears to go backwards before it moves ahead. I was treated for Hepatitis C with a combination of experimental drugs one from Giliead/Pharmassett one from BMS and guess what? I'm cured or precisely at nine months after finishing the drugs I am still virus free. 97% of other people in this trial are cured as well. But guess again these apparently safe drugs will not go into phase lll trial because Giliead wants to corner the market all by themselves, no partnership with BMS... I think this is BS as is some of the opinions expressed in this article about interferon.
    Sep 18, 2012. 03:44 PM | Likes Like |Link to Comment
  • This Week's Bio-Pharma Stock Movers: The Hep-C Market [View article]
    I'm closing in on week 24 (July 2=24 weeks) of follow up in the BMS/Gilead study...... still non detectable (no ribavirin in my study arm). The bummer is Gilead is dragging heals about entering into phase 3 even though this could be the silver bullet. It appears that compassion and capitalism don't mix.
    May 20, 2012. 11:18 PM | Likes Like |Link to Comment
COMMENTS STATS
4 Comments
0 Likes